Seelos Therapeutics to Participate in Two Investor Conferences
11/02/2021 - 08:00 AM
NEW YORK , Nov. 2, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim Healthcare Talks, Idea Forum, 3rd Annual Neuro/Immunology Day on November 15-16 th and in The Benchmark Company 10th Annual Discovery One on One Investor Conference on December 2 nd , 2021.
Guggenheim Healthcare Talks, Idea Forum, 3rd Annual Neuro/Immunology Day
Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 meetings virtually on Monday and Tuesday, November 15-16 th Yatin Suneja , Senior Biotechnology Analyst at Guggenheim Securities, LLC will host a fireside chat with Dr. Mehra on Tuesday, Nov. 16 th at 2:20pm ET For conference and fireside chat registration visit: https://guggenheim-neuro-immuno-conference-2021.videoshowcase.net/login The Benchmark Company 10th Annual Discovery One on One Investor Conference
Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 and small group meetings virtually on Thursday December 2 nd For registration and more information email: events@benchmarkcompany.com About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website: http://seelostherapeutics.com , the content of which is not incorporated herein by reference.
Contact Information:Anthony Marciano New York, NY 10022anthony.marciano@seelostx.com https://seelostherapeutics.com/ https://twitter.com/seelostx https://www.linkedin.com/company/seelos
https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-two-investor-conferences-301413478.html
SOURCE Seelos Therapeutics, Inc.
SEEL Rankings
#5248 Ranked by Stock Gains
SEEL Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Pharmaceuticals: Other, Biotechnology, Health Technology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
New York
About SEEL
seelos therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. the company's lead programs are sls-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; sls-005, a protein stabilizer for the treatment of sanfilippo syndrome; and sls-006, a partial dopamine agonist for the treatment of patients with parkinson's disease (pd). its preclinical programs include sls-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with pd; sls-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; sls-004 for the treatment of pd; sls-010, an oral histamine h3a receptor antagonist for narcolepsy a
